Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 11/20 | 0.56 |
| ▸ | CASP5 | P51878 | 11/20 | 0.56 |
| ▸ | CASP4 | P49662 | 9/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139052 | 0.81 | KDM4E (0.49) | CASP1CASP5CASP4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6772881 | 0.81 | KDM4E (0.48) | CASP1CASP5CASP4MEN1KMT2A | |
| SCHEMBL6139458 | 0.81 | KMT2A (0.72) | MEN1KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6139004 | 0.79 | KDM4E (0.47) | CASP1CASP5CASP4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6774817 | 0.79 | KDM4E (0.46) | CASP1CASP5CASP4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6774850 | 0.78 | ALDH1A1 (0.45) | CASP1CASP5CASP4MEN1KMT2A | |
| SCHEMBL9689427 | 0.78 | CASP1 (0.65) | CASP1CASP5CASP4KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL6778734 | 0.76 | ALDH1A1 (0.44) | CASP1CASP5CASP4MEN1KMT2A | |
| SCHEMBL7758530 | 0.76 | GAA (0.57) | MEN1KMT2AKDM4ELMNASMN1; SMN2 | |
| SCHEMBL8947821 | 0.76 | MEN1 (0.61) | MEN1KMT2AKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277746-B1 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-05-11 | — | — | EP | disclosed |
| US-6686360-B2 | ANTIISCHEMIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20030158207-A1 | N-benzylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-08-21 | — | — | US | disclosed |
| EP-1277746-A2 | N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof | Les Laboratoires Servier (FR) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158207-A1 | N-benzylpiperazine compounds | NPPA, BAD, GLS | CASP1 284/4885CASP5 89/4885CASP4 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.